Loss of tolerance precedes triggering and lifelong persistence of pathogenic type I interferon autoantibodies.
Journal
The Journal of experimental medicine
ISSN: 1540-9538
Titre abrégé: J Exp Med
Pays: United States
ID NLM: 2985109R
Informations de publication
Date de publication:
02 Sep 2024
02 Sep 2024
Historique:
received:
26
02
2024
revised:
10
05
2024
accepted:
21
06
2024
medline:
17
7
2024
pubmed:
17
7
2024
entrez:
17
7
2024
Statut:
ppublish
Résumé
Autoantibodies neutralizing type I interferons (IFN-Is) can underlie infection severity. Here, we trace the development of these autoantibodies at high-resolution using longitudinal samples from 1,876 well-treated individuals living with HIV over a 35-year period. Similar to general populations, ∼1.9% of individuals acquired anti-IFN-I autoantibodies as they aged (median onset ∼63 years). Once detected, anti-IFN-I autoantibodies persisted lifelong, and titers increased over decades. Individuals developed distinct neutralizing and non-neutralizing autoantibody repertoires at discrete times that selectively targeted combinations of IFNα, IFNβ, and IFNω. Emergence of neutralizing anti-IFNα autoantibodies correlated with reduced baseline IFN-stimulated gene levels and was associated with subsequent susceptibility to severe COVID-19 several years later. Retrospective measurements revealed enrichment of pre-existing autoreactivity against other autoantigens in individuals who later developed anti-IFN-I autoantibodies, and there was evidence for prior viral infections or increased IFN at the time of anti-IFN-I autoantibody triggering. These analyses suggest that age-related loss of self-tolerance prior to IFN-I immune-triggering poses a risk of developing lifelong functional IFN-I deficiency.
Identifiants
pubmed: 39017930
pii: 276862
doi: 10.1084/jem.20240365
pii:
doi:
Substances chimiques
Autoantibodies
0
Interferon Type I
0
Antibodies, Neutralizing
0
Interferon-alpha
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Swiss National Science Foundation
ID : 31003A_182464
Pays : Switzerland
Organisme : Novartis Foundation for Medical-Biological Research
ID : 23A069
Organisme : Promedica Foundation
Investigateurs
Irene A Abela
(IA)
Karoline Aebi-Popp
(K)
Alexia Anagnostopoulos
(A)
Manuel Battegay
(M)
Enos Bernasconi
(E)
Dominique Laurent Braun
(DL)
Heiner Bucher
(H)
Alexandra Calmy
(A)
Matthias Cavassini
(M)
Angela Ciuffi
(A)
Günter Dollenmaier
(G)
Matthias Egger
(M)
Luisa Elzi
(L)
Jan Fehr
(J)
Jacques Fellay
(J)
Hansjakob Furrer
(H)
Christoph Fux
(C)
Huldrych Fritz Günthard
(HF)
Anna Hachfeld
(A)
David Haerry
(D)
Barbara Hasse
(B)
Hans Hirsch
(H)
Matthias Hoffmann
(M)
Irene Hösli
(I)
Michael Huber
(M)
David Jackson-Perry
(D)
Christian Kahlert
(C)
Laurent Kaiser
(L)
Olivia Keiser
(O)
Thomas Klimkait
(T)
Roger Dimitri Kouyos
(RD)
Helen Kovari
(H)
Katharina Kusejko
(K)
Niklaus Labhardt
(N)
Karoline Leuzinger
(K)
Begogna Martinez de Tejada
(B)
Catja Marzolini
(C)
Karin Jutta Metzner
(KJ)
Nicolas Müller
(N)
Johannes Nemeth
(J)
Dunja Nicca
(D)
Julia Notter
(J)
Paolo Paioni
(P)
Giuseppe Pantaleo
(G)
Matthieu Perreau
(M)
Andri Rauch
(A)
Luisa Salazar-Vizcaya
(L)
Patrick Schmid
(P)
Roberto Speck
(R)
Marcel Stöckle
(M)
Philip Tarr
(P)
Alexandra Trkola
(A)
Gilles Wandeler
(G)
Maja Weisser
(M)
Sabine Yerly
(S)
Informations de copyright
© 2024 Fernbach et al.